Novo Nordisk A/S & Eli Lilly and Company cut prices for top diabetes drugs, boosting accessibility and potential revenue.
Palantir Technologies Inc. posts record earnings and raises guidance, but valuation concerns weigh on the stock. Click for my ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback